Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Share-based Compensation: 2022-2025

Historic Share-based Compensation for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $5.1 million.

  • Entrada Therapeutics' Share-based Compensation rose 5.27% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.0 million, marking a year-over-year increase of 16.97%. This contributed to the annual value of $17.9 million for FY2024, which is 36.64% up from last year.
  • Latest data reveals that Entrada Therapeutics reported Share-based Compensation of $5.1 million as of Q3 2025, which was up 1.35% from $5.0 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Share-based Compensation registered a high of $5.1 million during Q3 2025, and its lowest value of $1.8 million during Q1 2022.
  • Moreover, its 3-year median value for Share-based Compensation was $4.6 million (2024), whereas its average is $4.2 million.
  • Data for Entrada Therapeutics' Share-based Compensation shows a peak YoY surged of 53.57% (in 2023) over the last 5 years.
  • Over the past 4 years, Entrada Therapeutics' Share-based Compensation (Quarterly) stood at $2.9 million in 2022, then skyrocketed by 33.28% to $3.8 million in 2023, then grew by 22.36% to $4.7 million in 2024, then rose by 5.27% to $5.1 million in 2025.
  • Its Share-based Compensation was $5.1 million in Q3 2025, compared to $5.0 million in Q2 2025 and $5.1 million in Q1 2025.